Kamada (KMDA) Competitors $6.74 -0.09 (-1.25%) As of 11:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KMDA vs. AVDL, BHVN, EWTX, ARDX, SDGR, JANX, COGT, GPCR, ABCL, and TLRYShould you be buying Kamada stock or one of its competitors? The main competitors of Kamada include Avadel Pharmaceuticals (AVDL), Biohaven (BHVN), Edgewise Therapeutics (EWTX), Ardelyx (ARDX), Schrodinger (SDGR), Janux Therapeutics (JANX), Cogent Biosciences (COGT), Structure Therapeutics (GPCR), AbCellera Biologics (ABCL), and Tilray Brands (TLRY). These companies are all part of the "pharmaceutical products" industry. Kamada vs. Its Competitors Avadel Pharmaceuticals Biohaven Edgewise Therapeutics Ardelyx Schrodinger Janux Therapeutics Cogent Biosciences Structure Therapeutics AbCellera Biologics Tilray Brands Kamada (NASDAQ:KMDA) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Do institutionals and insiders have more ownership in KMDA or AVDL? 20.4% of Kamada shares are held by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are held by institutional investors. 36.1% of Kamada shares are held by insiders. Comparatively, 5.2% of Avadel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer KMDA or AVDL? In the previous week, Kamada had 5 more articles in the media than Avadel Pharmaceuticals. MarketBeat recorded 7 mentions for Kamada and 2 mentions for Avadel Pharmaceuticals. Kamada's average media sentiment score of 1.03 beat Avadel Pharmaceuticals' score of 0.56 indicating that Kamada is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kamada 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avadel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is KMDA or AVDL more profitable? Kamada has a net margin of 11.22% compared to Avadel Pharmaceuticals' net margin of -1.32%. Kamada's return on equity of 7.41% beat Avadel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Kamada11.22% 7.41% 5.18% Avadel Pharmaceuticals -1.32%-3.73%-1.73% Which has more risk and volatility, KMDA or AVDL? Kamada has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Which has preferable valuation and earnings, KMDA or AVDL? Kamada has higher earnings, but lower revenue than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKamada$169.52M2.28$14.46M$0.3419.81Avadel Pharmaceuticals$221.08M6.38-$48.83M-$0.03-484.17 Do analysts rate KMDA or AVDL? Kamada currently has a consensus price target of $13.00, suggesting a potential upside of 93.02%. Avadel Pharmaceuticals has a consensus price target of $20.86, suggesting a potential upside of 43.59%. Given Kamada's higher possible upside, equities analysts clearly believe Kamada is more favorable than Avadel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kamada 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Avadel Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 2.90 SummaryKamada beats Avadel Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Kamada News Delivered to You Automatically Sign up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KMDA vs. The Competition Export to ExcelMetricKamadaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$387.30M$3.36B$6.12B$10.57BDividend YieldN/A2.28%5.66%4.70%P/E Ratio19.8122.2286.0827.08Price / Sales2.28268.80534.29204.46Price / Cash13.8746.3226.3031.09Price / Book1.499.9712.726.66Net Income$14.46M-$52.35M$3.30B$275.86M7 Day Performance-1.97%6.36%4.34%3.06%1 Month Performance-5.67%12.02%7.82%10.52%1 Year Performance29.52%26.08%73.82%33.54% Kamada Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KMDAKamada4.5473 of 5 stars$6.74-1.2%$13.00+93.0%+31.2%$387.30M$169.52M19.81360Positive NewsAnalyst RevisionAVDLAvadel Pharmaceuticals3.1236 of 5 stars$16.00-1.2%$20.86+30.4%+14.7%$1.57B$169.12M-533.3370BHVNBiohaven3.1823 of 5 stars$14.92+4.2%$51.80+247.3%-66.7%$1.51BN/A-1.95239Positive NewsGap UpEWTXEdgewise Therapeutics2.7775 of 5 stars$15.10+5.9%$40.55+168.5%-44.9%$1.50BN/A-9.7460ARDXArdelyx4.1073 of 5 stars$6.22+0.2%$11.70+88.1%-22.9%$1.50B$333.61M-27.0490SDGRSchrodinger3.3654 of 5 stars$19.72+1.4%$27.83+41.1%+17.6%$1.43B$207.54M-7.95790Analyst DowngradeJANXJanux Therapeutics2.2508 of 5 stars$23.51+0.3%$78.31+233.1%-46.7%$1.41B$10.59M-13.0630COGTCogent Biosciences2.6422 of 5 stars$12.51+4.5%$20.00+59.9%+41.9%$1.36BN/A-7.0380GPCRStructure Therapeutics3.0948 of 5 stars$24.45+3.7%$75.71+209.7%-36.5%$1.36BN/A-23.29136ABCLAbCellera Biologics2.8772 of 5 stars$4.83+7.1%$8.00+65.6%+136.0%$1.35B$28.83M-8.78500TLRYTilray Brands2.723 of 5 stars$1.20-0.8%$1.94+61.5%-4.1%$1.33B$821.31M-0.522,842Upcoming Earnings Related Companies and Tools Related Companies Avadel Pharmaceuticals Alternatives Biohaven Alternatives Edgewise Therapeutics Alternatives Ardelyx Alternatives Schrodinger Alternatives Janux Therapeutics Alternatives Cogent Biosciences Alternatives Structure Therapeutics Alternatives AbCellera Biologics Alternatives Tilray Brands Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KMDA) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | Sponsored"I'm risking my reputation on this"My prediction: Q4 2025 won't just be another seasonal crypto pump. It will be the quarter that sparks a crypto...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWall Street legend: “Sell this A.I. stock now”Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | SponsoredThe next wave of AI fortunes may come from NVIDIA’s secret supplier.Bloomberg says AI is a $50 trillion revolution. And at the center of it… isn't NVIDIA. It's a tiny suppl...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kamada Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kamada With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
